Please login to the form below

Not currently logged in
Email:
Password:

CALD gene therapy

This page shows the latest CALD gene therapy news and features for those working in and with pharma, biotech and healthcare.

EMA accepts application for bluebird bio’s Lenti-D in CALD

EMA accepts application for bluebird bio’s Lenti-D in CALD

The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for bluebird bio’s Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD). ... Bluebird bio's Lenti-D (eli-cel/elivaldogene autotemcel) is a potential

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Europe is the test ground for the gene therapy pioneer’s outcomes-based model, which could set the standard for the emerging sector. ... pipeline. This incudes Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), a rare,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics